Castle Biosciences, Inc.

NASDAQ:CSTL

Medical - Diagnostics & Research

Healthcare
$33.38 +0.20%

+$0.04 today

Market cap
$1.03B
Beta
1.02
P/E (TTM)
-47.3
EPS (TTM)
-$0.43
52W Low $14.59High $44.28

Volume 0.38M

Average 0.37M

CSTL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Castle Biosciences, Inc.NASDAQ: CSTL

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 29.89M shares rose 4.5% year over year, ahead of the +0.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.9% from the prior quarter. Over 3 fiscal years it compounded at +3.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of +0.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
29.89M+1.9% QoQ
Last fiscal yearDec 2025
28.99M+4.4% YoY
LTMMar 2026
28.3M+0.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.5%——
1 year+4.4%——
3-year CAGR+3.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
28.99M USD
Year-over-year change
+4.4%
4-year CAGR
+3.6%

Weighted Avg Shares vs competitors

How CSTL compares with its peers on the latest reported figures

  • CSTL's LTM Mar 2026 weighted avg shares of 28.3M shares is the 7th highest of the 8 companies compared; the peer median is 93.15M shares.
  • Its year-over-year change of +0.9% is the lowest of 8, against a peer median of +2.8%.
  • Over three fiscal years its annual growth of +3.6% compares with a peer median of +7.1%.
CSTL Competitors Peer median
Weighted Avg Shares for CSTL and competitors
Company Period LTM YoY 3-year CAGR
GHGuardant Health, Inc.LTM Sep 2026131.61M +6.0%+7.1%
NEONeoGenomics, Inc.LTM Jun 2026128.84M +1.3%+1.0%
PSNLPersonalis, Inc.LTM Mar 202693.42M +36.5%+25.0%
MYGNMyriad Genetics, Inc.LTM Mar 202693.15M +2.4%+5.0%
VCYTVeracyte, Inc.LTM Jun 202679.27M +2.0%+3.2%
MDXHMDxHealth S.A.FY202550.03M +2.8%+46.6%
CSTLCastle Biosciences, Inc.LTM Mar 202628.3M +0.9%+3.6%
BDSXBiodesix, Inc.LTM Mar 20268.14M +14.9%+53.1%
FRNMFreenome, Inc. Common stock—— ——
Peer median (excluding CSTL) 93.15M+2.8%+7.1%

Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue94.09M137.04M219.79M332.07M344.23M
Cost of Revenue15.82M32.01M44.98M60.21M71.03M
Gross Profit78.26M105.03M174.81M271.86M273.2M
Gross Margin83.2%76.6%79.5%81.9%79.4%
Research & Development29.65M44.9M53.62M52.04M51.85M
Selling, General & Admin86.74M143M180.15M200.05M229.32M
Operating Expenses118.34M177.89M242.78M263.19M316.01M
Depreciation & Amortization3.41M10.54M12.33M16M40.77M
EBITDA(36.6M)(58.34M)(45.02M)38.14M11.34M
EBITDA Margin-38.9%-42.6%-20.5%11.5%3.3%
Operating Income(40.08M)(72.86M)(67.98M)8.67M(42.81M)
Operating Margin-42.6%-53.2%-30.9%2.6%-12.4%
Interest Income68K3.97M10.62M12.92M11.77M
Interest Expense1K17K11K577K86K
Other Income / Expenses67K3.95M10.61M12.89M13.3M
Income Before Tax(40.01M)(68.9M)(57.37M)21.56M(29.51M)
Pre-Tax Margin-42.5%-50.3%-26.1%6.5%-8.6%
Income Tax Expense(8.72M)(1.77M)101K3.32M(5.36M)
Net Income(31.29M)(67.14M)(57.47M)18.25M(24.16M)
Net Margin-33.3%-49.0%-26.1%5.5%-7.0%
EPS (Basic)(1.24)(2.58)(2.14)0.66(0.83)
EPS (Diluted)(1.24)(2.58)(2.14)0.62(0.83)
Weighted Avg Shares25.14M26.05M26.8M27.78M28.99M
Weighted Avg Shares (Diluted)25.14M26.05M26.8M29.26M28.99M

Castle Biosciences, Inc.

NASDAQ:CSTL

Intrinsic Alpha fair value

Locked

Current Price

$33.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.